Manuscripts are expected for all ORP approved studies. Additionally, submission of abstracts (prior to manuscript publication) for presentation are encouraged.  Please access the published manuscripts and abstracts in each disease state by clicking the links below:

Bibliography: NCCN Oncology Research Program Manuscripts

Bibliography: NCCN Oncology Research Program Abstracts

NCCN ORP Manuscripts

Angiosarcoma

Thiebaud J, Ravi V, Litwin S, Schuetze S, Movva S, Agulnik M, Kraft A, Tezlaff E, Somaiah N, von Mehren M.  A multicenter phase 2 study evaluating the role of pazopanib in angiosarcoma.  Cancer . 2022 Oct 1;128(19):3516-3522. doi: 10.1002/cncr.34403. Epub 2022 Aug 9 
https://pubmed.ncbi.nlm.nih.gov/35942596/

Breast Cancer

Datta J, Willingham N, Manouchehri JM, Schnell P, Sheth M, David JJ, Kassem M, Wilson TA, Radomska HS, Coss CC, Lustberg M, Ramaswany B, Stover DG, Cherian MA. Activity of Estrogen Receptor β Agonists in Therapy-Resistant Estrogen Receptor-Positive Breast Cancer. Front. Oncol., 25 April 2022 
https://doi.org/10.3389/fonc.2022.857590

Yam C, Rauch GM, Rahman T, Karuturi M, Ravenberg E, White J, Clayborn A, McCarthy P, Abouharb S, Lim B, Litton JK, Ramirez DL, Saleem S, Stec J, Symmans WF, Huo Lei, Damodaran S, Sun R, Moulder SL.  A Phase II Study of Mirvetuximab Soravtansine in Triple-Negative Breast Cancer.  Invest New Drugs 2021 Apr;39(2):509-515. doi: 10.1007/s10637-020-00995-2. Epub 2020 Sep 28.
https://pubmed.ncbi.nlm.nih.gov/32984932/

Heo GS, Detering L, Luehmann HP, Primeau T, Lee YS, Laforest R, Li S, Stec J, Lim KH, Lockhart AC, Liu Y. Folate receptor alpha targeted 89Zr-M9346A immuno-PET for image-guided intervention with mirvetuximab soravtansine in triple negative breast cancer. Mol Pharm. 2019 Sep 3;16(9):3996-4006. doi: 10.1021/acs.molpharmaceut.9b00653. Epub 2019 Aug 16 
https://www.ncbi.nlm.nih.gov/pubmed/31369274

Rimm DL, Han, G, Taube JM, Yi ES, Bridge JA, Flieder DB, Homer R, Roden AC, Hirsch FR, Wistuba II, Pusztai L, Reanalysis of the NCCN PD-L1 companion diagnostic assay study for lung cancer in the context of PD-L1 expression findings in triple-negative breast cancer. Breast Cancer Research (2019) 21:72.
https://doi.org/10.1186/s13058-019-1156-6

Gastrointestinal Cancer

Tella SH, Foster N, Qian S, Nguyen T, Borad MJ, McWilliams RR, Alberts SR, Ma WW, Chakrabarti S, Fruth B, Wessling J, Hartgers M, Washburn L, Fernandez-Zapico ME, Hogenson TL, Pitot H, Jin Z, Mahipal A. Phase II Trial of Trifluridine/Tipiracil Plus Irinotecan in Patients with Advanced, Refractory Biliary Tract Carcinoma. Oncologist. 2023 Jun 20:oyad144. doi: 10.1093/oncolo/oyad144. Epub ahead of print. PMID: 37339254.
https://pubmed.ncbi.nlm.nih.gov/37339254/

Malhotra U, Mukherjee S, Fountzilas C, Boland P, Miller A, Patnaik S, Attwood K, Yendamuri S, Adjei A, Kannisto E, Opyrchal M, Bushunow P, Loud P, Iyer R, Khushalani NI. Pralatrexate in combination with oxaliplatin in advanced esophago-gastric cancer: a phase II trial with predictive molecular correlates. Mol Cancer Ther. 2020 Jan;19(1):304-311. doi:10.1158/1535-7163.MCT-19-0240. Epub 2019 Oct 1.
https://pubmed.ncbi.nlm.nih.gov/31575653/

Burkart J, Owen D, Shah MH,  Abdel-Misih  S, Roychowdhury S,  Wesolowski R , Haraldsdottir S,  Reeser JW, Samorodnitsky E, Smith A, Konda B. Targeting BRAF Mutations in High-Grade Neuroendocrine Carcinoma of the Colon. J Natl Compr Canc Netw 2018 Sep;16(9):1035-1040 doi: 10.6004/jnccn.2018.7043.  
http://www.jnccn.org/content/16/9/1035.full

Gynecologic Cancer

Cristea MC, Stewart D, Synold T, Ruel N, Mortimer J, Wang E, Jung A, Wilczynski S, Konecyn GE, Eng M, Kilpattrick L, Han E, Dellinger H, Hakim A, Lee S, Morgan RJ, Wakabayashi T, Frankel PH.  A Phase I study of Mirvetuximab Soravtansine and gemcitabine in patients with FRα-positive recurrent ovarian, primary peritoneal, fallopian tube, or endometrial cancer, or triple negative breast cancer. Gynecologic Oncology Vol 182, p124-131, March 2024. https://doi.org/10.1016/j.ygyno.2023.12.017  

Cowan M, Swetzig WM, Adomo-Cruz V, Pineda MJ, Neubauer NL, Berry E, Lurain JR, Shahabi S, Taiym D, Nelson V, O'Shea KL, Kocherginsky M, Matei D. Efficacy and safety of tivozanib in recurrent, platinum-resistant ovarian, fallopian tube or primary peritoneal cancer, an NCCN phase II trial. Gynecol Oncol. 2021 Oct;163(1):57-63. doi: 10.1016/j.ygyno.2021.08.005. Epub 2021 Aug 18. https://pubmed.ncbi.nlm.nih.gov/34419285/

Kovisto CS, Parrish Santosh M, Bonala B, Ngoi S, Torres A, Gallagher J, Sanchez-Hodge R, Zeinner V, Nahhas GJ, Liu B, Cohn DE, Backs FJ, Goodfellow J, Chamberlin HM, Leone G.  Evaluating the efficacy of enzalutamide and the development of resistance in a preclinical mouse model of type-I endometrial carcinoma.  Neoplasia Volume 22, Issue 10, October 2020, Pages 484-496.  https://www.sciencedirect.com/science/article/pii/S1476558620301342

Liu JF, Gray KP, Wright AA, Campos S, Konstantinopoulos PA, Peralta A, MacNeill K, Morrissey S, whalen C, Dillon D, Matulonis US. Results from a single arm, single stage phase II trial of trametinib and GSK2141795 in persistent or recurrent cervical cancer. Gynecologic Oncology 154(2019) 95-101.
https://doi.org/10.1016/j.ygyno.2019.05.003

Head and Neck Cancer

Mudianto T, Campbell K, Webb J, Zolkind P, Skidmore Z, Riley R, Barnell E, Ozgenc I, Giri T, Dunn G, Adkins D, Griffith M, Egloff A, Griffith O, Uppaluri R.  Yap1 Mediates Trametinib Resistance in Head and Neck Squamous Cell Carcinomas. Clin Cancer Res. 2021 Apr 15;27(8):2326-2339.  doi: 10.1158/1078-0432.CCR-19-4179.  Epub 2021 Feb 5.
https://pubmed.ncbi.nlm.nih.gov/33547198/

Swiecicki PL, Bellile E, Brummell C, Brenner JC, Worden FP.  Efficacy of axitinib in metastatic head and neck cancer using novel radiographic response criteria.  Cancer 20 October 2020.
https://acsjournals.onlinelibrary.wiley.com/doi/10.1002/cncr.33226

Margalit DN, Haddad RI, Tishler RB, Chau NG, Schoenfeld JD, Bakst RL, Misiukiewicz KJ, Gupta V, Posner M, Hanna GJ, Mahmood U, Rawal B, Catalano PJ, Rath L, Bacay A, McHugh P, Rabinowits G. A Phase 1 Study of Afatinib in Combination with Postoperative Radiation Therapy With and Without Weekly Docetaxel in Intermediate- and High-Risk Patients with Resected Squamous Cell Carcinoma of the Head and Neck Int J Radiat Oncol Biol Phys. 2019 Sep 1;105(1):132-129. doi: 10.1016/j.ijrobp.2019.04.034. Epub 2019 May 11.
https://www.ncbi.nlm.nih.gov/pubmed?term=Margalit%2C+Danielle%5Bauthor%5D+AND+Afatinib&TransSchema=title&cmd=detailssearch

Teknos TN, Grecula J, Agrawal A, Old MO, Ozer E, Carrau R, Kang S, Rocco J, Blakaj D, Diavolitsis V, Kumar B, Kumar P, Pan Q, Palettas M, Wei L, Baiocchi R, Savvides P.  A phase 1 trial of Vorinostat in combination with concurrent chemoradiation therapy in the treatment of advanced staged head and neck squamous cell carcinoma. Invest New Drugs. 2019 Aug;37(4):702-710. doi: 10.1007/s10637-018-0696-4. Epub 2018 Dec 19.
https://www.ncbi.nlm.nih.gov/pubmed?term=Investigational+New+Drugs%5BJour%5D+AND+Teknos%5Bauthor%5D&cmd=detailssearch

Hematologic Cancer

Torka P,  Akhtar OS,  Reddy NM, Baysal BE,  Kader A, Groman A,  Nichols J, Mavis C,  Tario JD,  Block AM, Sait SN, Ghione P,  Sundaram S, PrzespolewskiER, Mohr A,  Lund I, Kostrewa J, McWhite K, DeMarco J, Johnson M, Darrall A, Thomas-Talley RN, Wallace PK, Neppalli V, Hutson A, Hernandez-Ilizaliturri FJ. Ofatumumab plus HyperCVAD/HD-MA induction leads to high rates of minimal residual disease negativity in patients with newly diagnosed mantle cell lymphoma: Results of a phase 2 study. Cancer 2022 Apr; 128(8):1595-1604. 
https://doi.org/10.1002/cncr.34106

Mehta-Shah N, Lunning MA, Moskowitz AJ, Boruchov AM, Ruan J, Lynch P, Hamlin PA, Leonard J, Matasar MJ, Myskowski PL, Marzouk E, Nair S, Sholklapper T, Minnal V, Palomba ML, Vredenburgh J, Kumar A, Noy A, Straus DJ, Zelenetz AD, Schoder H, Rademaker J, Schaffer W, Galasso N, Ganesan N, Horwitz SM. Romidepsin and lenalidomide-based regimens have efficacy in relapsed/refractory lymphoma: Combined analysis of two phase I studies with expansion cohorts. Am J Hematol. 2021 Oct 1;96(10):1211-1222. doi: 10.1002/ajh.26288. Epub 2021 Jul 29. PMID: 34251048
https://pubmed.ncbi.nlm.nih.gov/34251048/

Chow VA, Martin PS, Smith SD, Till BG, Graf SA, Edlefsen KL, Hannan LM, Mostaghel EA, Gopal AK.  Addressing the conundrum of male predominance in mantle cell lymphoma using androgen receptor blockade.  Br Journal of Haematol, First published: 22 June 2020, doi.org/10.1111/bjh.16902.
https://onlinelibrary.wiley.com/doi/full/10.1111/bjh.16902?af=R

Ma S, Rosen ST, Winqvist M, Frankfurt O, Winter JN, Gordon L, Helenowski I, Zhang H, Kreutzer J, Sönnert-Husa S,  Österborg A, Lundin J. Dual targeting fixed duration frontline monoclonal antibody therapy for chronic lymphocytic leukemia: A phase 2 study. Leukemia Research Volume 122, 2022, 106945, ISSN 0145-2126, https://doi.org/10.1016/j.leukres.2022.106945 

Lampson BL, Kim HT, Davids MS, Abramson JS,  Freedman AS, Jacobson CA, Armand PA, Joyce RM, Arnason JE, Rassenti LZ,  Kipps TJ, Fein J,  Fernandes SM, Hanna JR, Fisher DC, and  Brown JR. Efficacy results of a phase 2 trial of first-line idelalisib plus ofatumumab in chronic lymphocytic leukemia. Blood Advances  2019 3:1167-1174.
https://doi.org/10.1182/bloodadvances.2018030221

Vitale C, Falchi L, Ciccone M, Burger J, Pemmaraju N, Borthakur G,  Wierda WG, Keating MJ, and Ferrajoli A. Ofatumumab is safe and effective as front-line treatment in older patients with chronic lymphocytic leukemia and severe co-morbidities, including other malignancies.  J Geriatr Oncol. 2020 Jan;11(1):19-23. doi: 10.1016/j.jgo.2019.04.002. Epub 2019 Apr 18.
https://www.ncbi.nlm.nih.gov/pubmed/31005650

Hepatocellular Carcinoma

Kelley RK, Joseph NM, Nimeiri HS, Hwang J, Kulik LM, Ngo Z, Behr SC, Onodera C, Zhanag K, Bocobo AG, Benson AB, Venook AP, Gordon JD. Temsirolimus combined with sorafenib in hepatocellular Carcinoma with Tumor Mutation Profiling. Liver Cancer 2021. doi: 10.1159/000518297 https://www.karger.com/Article/FullText/518297

El Dika I, Capanu M, Chou JF, Harding J, Ly M, Hrabovsky A, Do R, Shia J, Millang B, Ma J, O'Reilly E, Abou-Alfa G. Phase II trial of sorafenib and doxorubicin in patients with advanced hepatocellular carcinoma after disease progression on sorafenib. Cancer Med. 2020;00:1–7. https://doi. org/10.1002/cam4.3389
https://doi.org/10.1002/cam4.3389

Harding, JJ, Kelley RK, Tan B, Capanu M, Lobst, Do R, Shia J, Chou JF, Boussayoud C, Ferrere C, Muenkel KE, Yarmohammadi H, El Dika I, Khalil D, Ruiz , Rodriguez MR, Kuhn P, Wilton J, Iyer R, Abou-Alfa GK. Phase 1b study of enzalutamide with or without sorafenib in patients with advanced hepatocellular carcinoma.  The Oncologist on line 16 June 2020
https://theoncologist.onlinelibrary.wiley.com/doi/full/10.1634/theoncologist.2020-0521

Kalathil SG, Hutson A, Barbi J, Iyer R, Thanavala Y.  Augmentation of IFN-γ+ CD8+ T cell responses correlates with survival of HCC patients on sorafenib therapy.  JCI Insight.  2019;4(15):e130116.
https://doi.org/10.1172/jci.insight.130116

Lung Cancer

Dy G, Prasad D, Kumar P, Attwood K, Adjei A.  A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study Evaluating Nintedanib Versus Placebo as Prophylaxis Against Radiation Pneumonitis in Patients With Unresectable NSCLC Undergoing Chemoradiation Therapy.  J Thorac Oncol. 2021 Mar;16(3):e19-e20.  doi: 10.1016/j.jtho.2020.11.019.
https://pubmed.ncbi.nlm.nih.gov/33641724/

Neal JW, Costa D, Muzikansky A, Shrager J, Lanuti M, Huang J, Ramachandran K, Rangaschari D, Huberman M, Piotrowski Z, Kris M, Azzoli C, Sequist L, Chaft J .  Randomized Phase II Study of 3 Months or 2 Years of Adjuvant Afatinib in Patients with Surgically Resected Stage I-III EGR-Mutant Non-Small-Cell Lung Cancer.  JCO Precision Oncology No.5(2021) 325-332.  Published online 2/2/21. DOI: 10.1200/PO.20.00301
https://ascopubs.org/doi/full/10.1200/PO.20.00301?journalCode=po

Owen DH, Williams TM, Bertino EM, Xiaokui Mo, Webb A, Schweitzer C, Liu T, Roychowdhury S,  Timmers CD, Otterson GA  Homologous recombination and DNA repair mutations in patients treated with carboplatin and nab-paclitaxel for metastatic non-small cell lung cancer. Lung Cancer 134 (2019) 167–173. 
https://doi.org/10.1016/j.lungcan.2019.06.017

Melanoma

Nebhan CA, Johnson DB, Sullivan RJ, Amaria RN, Flaherty KT, Sosman JA, Davies MA. Efficacy and Safety of Trametinib in Non-V600 BRAF Mutant Melanoma: A Phase II Study. The Oncologist. 2021 Apr 16. doi: 10.1002/onco.13795. https://theoncologist.onlinelibrary.wiley.com/doi/10.1002/onco.13795

Neuroendocrine Tumors

Iyer RV, Konda B, Fountzilas C, Mukherjee S, Owen D, Attwood K, Wang C, Suffren S, Hicks K, Wilton J, Bies, R, Casucci D, Reidy-Lagunes D, Shah M.   Multicenter phase 2 trial of nintedanib in advanced nonpancreatic neuroendocrine tumors. Cancer. 2020 Aug 15;126(16):3689-2697. Epub 2020 Jun 11. doi:10.1002/cncr.32994
https://pubmed.ncbi.nlm.nih.gov/32525561/

Peritoneal

Cristea MC, Frankel P, Synold T, Rivkin S, Lim D, Chung V, Chao J, Wakabayashi M, Paz B, Han E, Lin P, Leong L, Hakim A, Carroll M, Prakash N, Dellinger T, Park M, Morgan RJ. A phase I trial of intraperitoneal nab-paclitaxel in the treatment of advanced malignancies primarily confined to the peritoneal cavity. Cancer Chemother Pharmacol. 2019 Mar;83(3):589-598. doi: 10.1007/s00280-019-03767-9. 
https://www.ncbi.nlm.nih.gov/pubmed/30623229

Prostate Cancer

Shee K, de la Calle C, Chang A, Wong, A, Feng F, Gottschalk A, Carroll P, Nguyen H. Addition of Enzalutamide to Leuprolide and Definitive Radiation Therapy Is Tolerable and Effective in High-Risk Localized or Regional Nonmetastatic Prostate Cancer: Results From a Phase 2 Trial, Shee, Kevin et al, Advances in Radiation Oncology, Volume 7, Issue 5, 100941, March 11, 2022. 
https://www.advancesradonc.org/article/S2452-1094(22)00048-3/fulltext

Quality Improvement

Wright AA, Poort H, Tavormina A, Schmiege SJ, Matulonis UA, Campos SM, et al. Pilot randomized trial of an acceptance-based telehealth intervention for women with ovarian cancer and PARP inhibitor-related fatigue. Gynecologic Oncology. 2023 Oct 1;177:165–72. 
https://doi.org/10.1016/j.ygyno.2023.08.020 

Aggarwal C, Marmarelis ME, Hwang W-T, Scholes DG, McWilliams TL, Singh AP, Sun L, Kosteva J, Costello MR, Cohen RB, Langer CL, Doucette A, Gabriel PN, Shulman LN, Rendle KA, Thompson JC, Bekelman JE, Carpenter EL. Association Between Availability of Molecular Genotyping Results and Overall Survival in Patients With Advanced Nonsquamous Non–Small-Cell Lung Cancer. DOI: 10.1200/PO.23.00191 JCO Precision Oncology no. 7 (2023) e2300191. Published online July 27, 2023.
https://ascopubs.org/doi/pdf/10.1200/PO.23.00191?role=tab

Fleege N, Pierce-Gjeldum D, Swartz LK, Verbal K, Merajver S, Friese CR, Kiyota A, Heth J, Leung D, Smith SR, Gabel N, Kim MM, Morikawa A. IMPACT the Brain: A Team-Based Approach to Management of Metastatic Breast Cancer with Central Nervous System Metastases. JCO Oncol Pract. 2023 Jan;19(1):e67-e77. doi: 10.1200/OP.22.00291. Epub 2022 Oct 12.
https://pubmed.ncbi.nlm.nih.gov/36223556/ 

Wickline M, Wolpin S, Cho S, Tomashek H, Louca T, Frisk T, Templin J, Loechl A, Goff B, Berry D. Usability and acceptability of the electronic self-assessment and care (eSAC) program in advanced ovarian cancer: A mixed methods study. Gynecol Oncol. 2022 Sep 20:S0090-8258(22)01825-X. doi: 10.1016/j.ygyno.2022.09.010. Epub ahead of print. PMID: 36150917.
https://pubmed.ncbi.nlm.nih.gov/36150917/

Waldman LP, Centracchio JA, Jacobs JM, Petrillo LA, El-Jawahri AR, Temel JS and Greer JA (2023) Study protocol for a randomized trial of a supportive care mobile application to improve symptoms, coping, and quality of life in patients with advanced non-small cell lung cancer. Front. Psychol. 14:1184482. doi: 10.3389/fpsyg.2023.1184482.
https://www.frontiersin.org/articles/10.3389/fpsyg.2023.1184482/full

Rectal Cancer

Wu C, Williams TM, Robb R, Webb A, Wei L, Chen W, Mikhail S, Ciombor KK, Cardin DB, Timmers C, Krishna SG, Arnold M, Harzman A, Abdel-Misih S, Roychowdhury S, Bekaii-Saab T, Wuthrick E. Phase I Trial of Trametinib with Neoadjuvant Chemoradiation in Patients with Locally Advanced Rectal Cancer.  Clin Cancer Res. 2020 26(13):3117-3125. doi: 10.1158/1078-0432.CCR-19-4193.
https://doi.org/10.1158/1078-0432.CCR-19-4193

Solid Tumors

Haraldsdottir S, Janku F, Poi M, Timmers C, Geyer S, Larry J, Schaaf LJ, Sexton J, Wei L, Thurmond J, Velez-Bravo V, Stepanek VM, Bertino EM, Kendra K, Mortazavi A, Subbiah V, Phelps M,  Shah MH. A phase I trial of dabrafenib and pazopanib in BRAF mutated advanced malignancies. JCO Precision Oncology, published online May 14, 2018.
https://ascopubs.org/doi/full/10.1200/PO.17.00247

Thyroid Cancer

Busaidy NL, Konda B, Wei L, Wirth LJ, Devine C, Daniels GA, DeSouza JA, Poi M, Seligson ND, Cabanillas ME, Sipos JA, Ringel MD, Eisfeld AK, Timmers C, Shah MH. Dabrafenib Versus Dabrafenib + Trametinib in BRAF-Mutated Radioactive Iodine Refractory Differentiated Thyroid Cancer: Results of a Randomized, Phase 2, Open-Label Multicenter Trial. Thyroid. 2022 Jul 5. doi: 10.1089/thy.2022.0115. Online ahead of print.
https://pubmed.ncbi.nlm.nih.gov/35658604/ 

Kurzrock R, Ball DW, Zahurak ML, Nelkin BD, Subbiah V, Ahmed S, O'Connor A, Karunsena E, Parkinson RM, Bishop JA, Ha Y, Sharma R, Gocke CD, Zinner R, Rudek MA, Sherman SI, Azad NS. The VEGF Receptor Tyrosine Kinase Inhibitor Pazopanib in Combination with the MEK Inhibitor Trametinib in Advanced Solid Tumors and Differentiated Thyroid Cancers. Clin Cancer Res. 2019 Sep 15;25(18):5475-5484. doi: 10.1158/1078-0432.CCR-18-1881. Epub 2019 Jun 11. PMID: 31186313. 
https://www.ncbi.nlm.nih.gov/pubmed/31186313

Owen D, Konda B, Sipos J, Liu T, Webb A, Ringel M., Timmers C, Shah MH. KRAS G12V Mutation in Acquired Resistance to Combined BRAF and MEK Inhibition in Papillary Thyroid Cancer J Natl Compr Canc Netw 2019;17(5):409–413 doi: 10.6004/jnccn.2019.7292.
https://www.ncbi.nlm.nih.gov/pubmed/31085763

NCCN ORP Abstracts

Brain Cancer

Ly I, Richardson L, Liu M, Muzikansky A, Lou K, Reardon DA, Arrillaga-Romany I, Forst DA, Jordan JT, Lee EQ, Dietrich J, Nayak L, Wen PY, Chukwueke UN, Giobbie-Hurder A, Choi BD, Batchelor T, Kalpathy-Cramer J, Curry WT, Gerstner ER. Phase 2 trial of bavituximab with chemoradiation and adjuvant temozolomide in newly diagnosed glioblastoma. J Clin Oncol 40, 2022 (suppl 16; abstr 2030).
https://ascopubs.org/doi/abs/10.1200/JCO.2022.40.16_suppl.2030

Ly I, Cardona J, Beers A, Chang K, Brown J, Reardon D, Arrillaga-Romany I, Dietrich J, Forst D, Lee E, Jordan J, Nayak L, Wen P, Batchelor T, Kalpathy-Cramer J, Gerstner E. NIMG-68. MRI Changes in Newly Diagnosed Glioblastoma Patients Treated as Part of a Phase II Trial with Bavituximab, Radiation, and Temozolomide.  Neuro-Oncology, Volume 20, Issue suppl_6, 5 November 20
https://doi.org/10.1093/neuonc/noy148.792

Dauki A, He L, Ling Y, Sekhon A, Kendra K, Cavaliere R, Welliver M, McGregor J, Wei L, Mrozek E, Olencki T, Thelen J, Prevedello D, Thoman W, Matharbootham M, Ammirati M, Coss C, Grecula J, Phelps M. Drug Quantification in Metastatic Brain Tumors in Patients Receiving Bendamustine as a Radiosensitizer for Stereotactic Radiothera.  J Clin Oncol 36, 2018 (suppl; abstr e14017).
https://meetinglibrary.asco.org/record/164019/abstract

Breast Cancer

HelgasonT, Damodaran S, Hess KR, Symmans WF, Moulder SL. Folate Receptor alpha (FRα) Expression in Metastatic Triple-Negative Breast Cancer (TNBC). J Natl Compr Canc Netw  (Abstract ). J Natl Compr Canc Netw Mar2019; vol 17 issue 3.5 (Abstract CLO19-036).
https://doi.org/10.6004/jnccn.2018.7115

Heo GS,Detering L, Luehmann HP, Primeau T, Shunqiang Li S, Stec J, Kian H, Lim KH, Lockhart AC, Liu Y. 89Zr-M9346A immuno-PET imaging folate receptor alpha in triple negative breast cancer for image-guided intervention with mirvetuximab Soravtansine.  J Nucl Med May 1, 2018 vol. 59 no. supplement 1 174.
https://jnm.snmjournals.org/content/59/supplement_1/174.abstract?sid=ca2dbe76-5963-4e6c-8e28-997610cbbd61 

Carcinoid Cancer 

Iyer R, Konda B, Owen D, Attwood K, Sarker S, Suffren S, Wilton J, Bies R, Reidy D, Shah, M. Multicenter Phase 2 Study of Nintedanib in Patients (pts) with Advanced Progressing Carcinoid Tumors. NANETS 2018 Symposium Abstract C-14. 
https://nanets.org/abstracts-archive/2018/886-abstract-c14/file

Iyer R, Konda B, Attwood K, Sarker S, Suffren SA, Wilton J, Bies, R, Casucci D, Reidy D, Shah M.  Title: Multicenter Phase 2 Study of Nintedanib in patients (pts) with advanced progressing carcinoid tumors.    J Clin Oncol 36, 2018 (suppl; abstr 4105).
https://nanets.net/abstracts-archive/2017/599-t04-multicenter-phase-2-study-of-nintedanib-in-patients-pts-with-advanced-progressing-carcinoid-tumors/file

Gastrointestinal Cancer

Mukherjee S, Alarcon S, Fountzilas C, Chatley S, Iyer R, Vadehra D, Kukar M, Attwood K, George A, Brown A, Liao C, Hatoum H, George S. Trifluridine/tipiracil (FTD/TPI) and oxaliplatin as induction chemotherapy (IC) in resectable esophageal and gastroesophageal junction adenocarcinoma (EGAC): Preliminary results from a phase II study [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2023; Part 2 (Clinical Trials and Late-Breaking Research); 2023 Apr 14-19; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2023;83(8_Suppl):Abstract nr CT146.
https://doi.org/10.1158/1538-7445.AM2023-CT146

Boland PM, Mukherjee S, Imanirad I, Vijayvergia N, Cohen SD, Gupta M, Iyer RV, Chatley S, Cahill B, Vadehra D, Attwood K, Hochster HS, Fountzilas C.  Phase II study of biweekly TAS-102, irinotecan and bevacizumab in pre-treated metastatic colorectal cancer (TABAsCO). J Clin Oncol 41, 2023 (suppl 16; abstr 3590).
https://meetings.asco.org/abstracts-presentations/220278  

Gupta, M, Fountzilas C, Vijayvergia N, Attwood K, Hochster HS, Mukherjee S, Iyer R, Boland PM. A Phase II Study of Trifluridine/tipiracil, Irinotecan and Bevacizumab in Pre-treated Metastatic Colorectal Cancer (TABAsCO). Journal of Clinical Oncology 38, no. 4_suppl.  Published on line February 04, 2020. 
https://ascopubs.org/doi/abs/10.1200/JCO.2020.38.4_suppl.TPS275

Xie H, Borad MJ,  Ahn DH, Bekaii-Saab TS, Tran NH, Jin Z, Pitot HC, Huebner LJ, Shi Q, Wessling J, Durgin LM,  Liu MC, Hogenson TL, Phillips WJ, Fernandez-Zapico M, Alberts SR, Mahipal A.  Phase II trial of trifluridine/tipiracil and irinotecan for the treatment of advanced refractory biliary tract cancer. Journal of Clinical Oncology 38, no. 4_suppl.  Published on line February 04, 2020. 
https://ascopubs.org/doi/abs/10.1200/JCO.2020.38.4_suppl.TPS594

Mukherjee S,  Assi H, Fountzilas C, Attwood K, Boland P, Iyer R, Catenacci DV,  Hatoum H.  Phase II Study of Trifluridine/Tipiracil (FTD/TPI) and Oxaliplatin as Induction Chemotherapy (IC) in Resectable Esophageal and Gastroesophageal Junction Adenocarcinoma (EGAC)Journal of Clinical Oncology 38, no. 4_suppl.  Published on line February 04, 2020. 
https://ascopubs.org/doi/abs/10.1200/JCO.2020.38.4_suppl.TPS464

Kircher S, Kalyan A, Berlin J, Mulcahy M, Cohen S, Denlinger C, Chiorean E, Sahai V, Zalupski M, Rademaker A, Benson A, Nimeiri H, Bhave M.  A Phase I/II Study of the Combination of Temozolomide(TM) and Pazopanib (PZ) in Advanced Well-Differentiated Pancreatic Neuroendocrine Tumors (PNETs) (NCT01465659). J Clin Oncol 36, 2018 (suppl; abstr 4096).
https://meetinglibrary.asco.org/record/160115/abstract

Boland P, Fakih M, Lim D, Attwood K, Tan W, Ebos J, Mastri M, Bies R, Fountzilas C, Iyer R, Ma W.  A phase I/II study of nintedanib and capecitabine in refractory metastatic colorectal cancer.J Clin Oncol 36, 2018 (suppl; abstr 3552).
https://meetinglibrary.asco.org/record/158840/abstract

Lee S, Krishnamurthi S, Miller A, Estfan B, Wang C, Frazer A, Iyer R . Correlation of overall survival (OS) in patients (pts) with inoperable hepatocellular carcinoma (iHCC) receiving tivozanib (TIVO) with baseline performance status. J Clin Oncol 36, 2018 (suppl; abstr e16122).
https://meetinglibrary.asco.org/record/164506/abstract

Lee S, Miller A, Krishnamurthi S, Estfan B, Frazer A, Wang C, Iyer I. Phase 1b/2 study of tivozanib in patients with advanced inoperable hepatocellular carcinoma. J Clin Oncol 36, 2018 (suppl 4S; abstr 364)
https://meetinglibrary.asco.org/record/156045/abstract 

Gynecologic Cancer

Cristea MC, Ruel NH, Frankel PH, Synold TW, Stewart DB, Wang EW, Jung A, Wilczynski S, Tran M, Konecyn GE, Eng M, Kilpatrick L, Chen Y, Glaser S, Dellinger TH, Hakim A, Lee S, Morgan R, Han ES. A phase I study of mirvetuximab soravtansine (MIRV) and gemcitabine (G) in patients (Pts) with selected frα-positive solid tumors: Results in the ovarian cancer (EC) cohort. J Clin Oncol 39, 2021 (suppl 15; abstr 5542) https://meetinglibrary.asco.org/record/197431/abstract

Westin SN, Fellman B, Yuan Y, Soliman PT, Fleming ND, Cobb L, Shafer A, Taylor J, Jazaeri A, Frumovitz M, Ramirez PT, Meyer LA, Alvarado T, Hull S, Lu KH, Mills GB, Coleman RL. ENPAC: Phase II trial with a limited safety lead of enzalutamide in combination with paclitaxel and carboplatin for advanced and recurrent endometrioid endometrial adenocarcinoma. SUNDAY_2021- SGO Virtual-Annual-Meeting-on-Womens-Cancer.

Cristea MC, Frankel P, Synold T, Stewart DB, Wang E, Jung A, Wilczynski S, Tran M, Konecny GE, Eng M, Kilpatrick L, Chen Y, Glaser S, Han E, Dellinger T, Hakim A, Lee S, Morgan RJ, Rodriguez L, Wakabayashi M.  A Phase I Study of Mirvetuximab Soravtansine (MIRV) and Gemcitabine (G) in Patients (Pts) with selected FRα -positive solid tumors: Results in the Endometrial Cancer (EC) Cohort.  Annals of Oncology (2020) 31 (suppl_4): S551-S589. 10.1016/annonc/annonc276
https://www.annalsofoncology.org/article/S0923-7534(20)40998-6/fulltext

Chelariu-Raicu A, Stur E, Ivan C, Coleman RL, Sood AK, Wen Y. Biological effects of a FRα-targeting antibody-drug conjugate, IMGN853 (mirvetuximab soravtansine) in high-grade serous ovarian cancer. In: Proceedings of the 111th Annual Meeting of the American Association for Cancer Research; 2020 June 22-24. Philadelphia (PA): AACR; 2020. Abstract 1237/20
https://www.abstractsonline.com/pp8/#!/9045/presentation/3480

Khan R, Stets C, Demoret B, Chen JL, Hays JL. Increasing Folate Receptor Alpha Expression With Chemotherapy and Hormonal Agents Improves Activity of Mirvetuximab Soravtansine (IMGN853) in Endometrial Cancer. JNCCN (2018;16(5.5):575-673 https://jnccn.org/abstract/journals/jnccn/16/5S/article-pe-1.pdf

Hopp E, Joseph P, Nakayamaa J, Zanottia KM, Nagela CI, Waggonera SE,  DiFeo A. Identifying susceptibilities and pharmacodynamic biomarkers for mirvetuximab soravtansine in high-grade ovarian and endometrial cancer. Gynecologic Oncology, Volume 149, 57. 
https://doi.org/10.1016/j.ygyno.2018.04.126

Wen Y, Bartsch F, Ivan C, Sood AK. Anti-Folate Receptor Antibody Directed, Antibody-Drug Conjugate Induces Autophagy Cell Death in High-Grade Serous Ovarian Cancer. JNCCN (2018;16(5.5):575-673.
Link:  https://jnccn.org/abstract/journals/jnccn/16/5S/article-p582.pdf

Cristea MC, Frankel P,  Synold T,  Mortimer J, Stewart D, Wang E, Jung1 A, Wilczynski S, Konecny GE, Parungao D, Eng M, Kilpatrick L,  Chen YJ, Glaser S, Han E, Dellinger T, Hakim A,  Lee S, Morgan RJ, Wakabayashi M. A Phase I Study of Mirvetuximab Soravtansine (IMGN853) and Gemcitabine (G) in Patients with FOLR1-positive Recurrent Epithelial Ovarian (EOC), Endometrial Cancer (EC), or Triple Negative Breast Cancer (TNBC). J Clin Oncol 37, 2019 (suppl; abstr 3009). 
https://meetinglibrary.asco.org/record/174209/abstract

Swetzig WM, Lurain JR, Berry E, Pineda MJ, Shahabi S,  Perry L, Neubauer NL, Nieves-Neira W, Schink JC,  Schiller A, Novak K, Anderson N, Burdett K,  Strohl AE, Kocherginsky M, and Matei DE. Efficacy and Safety of Tivozanib in Recurrent, Platinum-Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer.  J Clin Oncol 37, 2019 (suppl; abstr 5538).
https://meetinglibrary.asco.org/record/175508/abstract

Hematologic Cancer

Chow VA, Martin PS, Smiith SD, Till BG, Solomon AG, Kerstin JE, Hannan LM, Mostaghel EA, Gopal, AK.  Androgen Receptor Targeting in Mantle Cell Lymphoma: A Pilot Trial of Enzalutamide. Blood (2019) 134 (Supplement_1): 5254.
https://doi.org/10.1182/blood-2019-125462

Kambhampati S, Fakhri B, Ai W,  Kaplan LD, Tuscano J,  Wieduwilt MJ , Sudhindra A,   Hwang J, Reiner J, Martinelli M, Aoun C, Ta T , Le D, Padilla M, Crawford E, Andreadis C. A Phase 1b Dose Escalation Trial of Carfilzomib in Combination with Bendamustine and Rituximab in Patients with Relapsed or Refractory Non-Hodgkin Lymphoma. Blood (2019) 134 (Supplement_1): 2828.
https://doi.org/10.1182/blood-2019-123279

Torka P; Reddy N; Kader A; Groman A; Hutson A; Mavis C; Block A; Sait S; Baysal B; Neppalli V; Tario J; Wallace P; Sundaram S; Hernandez-Ilizaliturri F. A Phase 2 Study of Ofatumumab in Combination With HYPER-CVAD/MA in Patients With Newly Diagnosed Mantle Cell Lymphoma. HemaSphere: June 2019 - Volume 3 - Issue - p 105–106
https://journals.lww.com/hemasphere/Fulltext/2019/06001/A_PHASE_2_STUDY_OF_OFATUMUMAB_IN_COMBINATION_WITH.205.aspx

Hepatocellular Carcinoma 

Harding J, Kelley R, Tan B, Iobst E, Boussayoud C, Muenkel K,  Do R, Chou J, Capanu M, Ruiz C, Lee M, Wilton Iyer R, Abou-Alfa G. Phase 1B study of enzalutamide (ENZA) with or without sorafenib (SORA) in patients (pts) with advanced hepatocellular carcinoma (HCC).  J Clin Oncol 36, 2018 (suppl; abstr 4083).
https://meetinglibrary.asco.org/record/160161/abstract

Lung Cancer 

Bodor JB, Patel JD, Ross EA, Litwin S, Clapper M, Levy BP, Wakelee HA, Borghaei H, Treat J: Phase II randomized trial of carboplatin + pemetrexed + bevacizumab, +/- atezolizumab in stage IV non-squamous non-small lung cancer (NSCLC) patients who harbor a sensitizing EGFR mutation or have never smoked. J Clin Oncol 38: 2020
https://meetinglibrary.asco.org/record/191802/abstract 

Waqar SN, Rawat U, Morgensztern D, Shah S, Ward JP, Devarakonda SH, Rearden TP, Gao F, Govindan R. A pilot study of nintedanib in molecularly selected patients with advanced non-small cell lung cancer (NSCLC) (NCT02299141). J Clin Oncol 38: 2020 (suppl; abstr e21694). 
https://meetinglibrary.asco.org/record/185721/abstract

Chaft JE, Costa DB, Muzikansky A, Shrager JB, Lanuti M, Huang J, Ramchandran J, Rangachari D, Huberman M, Piotrowski Z, Kris MG, Azzoli J, Sequist L, Neal JW.  Randomized Phase II Study of Adjuvant Afatinib for 3 Months vs 2 Years in Patients with Resected Stage I-III EGFR Mutant NSCLC.  J Clin Oncol 37, 2019 (suppl; abstr 8507).
https://meetinglibrary.asco.org/record/173513/abstract

Elamin YY, Antonoff M, Blakely C, Baggstorm M, Bivona T,  Lei X, Louie AV, Doebele RC, Rusthoven C, Lee P, Govindan R, Swisher S C, Papadimitrakopoulou VA, Heymach JV, Gomez DR. 1509Tip. Randomized phase II trial of osimertinib with or without local consolidation therapy (LCT) for patients with EGFR-mutant metastatic NSCLC (NORTHSTAR). Annals of Oncology, Volume 29, Issue suppl_8, 1 October 2018, mdy292.130.
https://doi.org/10.1093/annonc/mdy292.130

Owen DH, Bertino EM, Williams TM, Mo X, Timmers CD, Webb A, Roychowdhury S, Villalona-Calero MA, Otterson GA. AB2018-77. Mutation Analysis of a Prospective Phase II Trial of Carboplatin and Nab-Paclitaxel for Metastatic Non–Small Cell Lung Cancer. J Natl Compr Canc Netw 2018;16:e-1-e-55. http://www.jnccn.org/content/16/5S/e-1.full#sec-4 

Prostate Cancer

Roy AM, Gopalakrishnan D, Jatwani K, Green K, Farmer B, Jaiswal N, Attwood K, Levine EG, Beltran H, Goodrich D, Chatta GS.  A phase Ib trial of enzalutamide with oral decitabine/cedazuridine in metastatic castration-resistant prostate cancer (CRPC).   J Clin Oncol 42, 2024 (suppl 4; abstr TPS252). https://meetings.asco.org/abstracts-presentations/230435

de la Calle CM, Chang, A, Rashid G, Wong AC, Choi A, Feng FY, Gottschalk AR, Menzel PL , Carroll P, Nguyen HG.  Phase II trial of definitive radiotherapy with leuprolide and enzalutamide in high-risk prostate cancer.  J Clin Oncol 38, 2020 (suppl 6; abstr 323).  
https://meetinglibrary.asco.org/record/183514/abstract

Quality Improvement Studies

Marmarelis ME, Scholes DG, McWilliams TL, Hwang W-T, Kosteva JA, Costello MR, Sun LL, Singh AP, Lau-Min KS, Doucette A, Gabriel PE, Martella AO, Roy M, Thompson JC, Cohen RB, Dougherty DW, Shulman LN, Langer CJ, Bekelman JE, Carpenter EL, Aggarwal C. Prospective Trial of an EMR-based Nudge to Increase Molecular Genotyping in Newly Diagnosed Metastatic Non-squamous NSCLC. Abstract MA14.04, 2023 World Conference on Lung Cancer, September 11, 2023. https://cattendee.abstractsonline.com/meeting/10925/Session/113

Wright AA, Poort H, Tavormina A, Schmiege S, Matulonis UA, Campos SM, Liu JF, Slivjak E, Gilmour A, Salinger J, Haggerty AF, Arch JA. Pilot randomized trial of a telehealth intervention for women with advanced ovarian cancer and PARP inhibitor-related fatigue. Journal of Clinical Oncology 2023 41:16_suppl, e24122-e24122. 
https://meetings.asco.org/abstracts-presentations/225422  

Aggarwal C, Marmarelis ME, Hwang W-T, Scholes DG, McWilliams T, Singh AP, Sun L, Kosteva JA, Costello MR, Cohen RB, Langer CL, Gabriel PE, Shulman LN, Thompson JC, Carpenter EL. Association of comprehensive molecular genotyping and overall survival in patients with advanced non-squamous non-small cell lung cancer. Journal of Clinical Oncology 2022 40:16_suppl, 9022-9022.
https://ascopubs.org/doi/10.1200/JCO.2022.40.16_suppl.9022

Bruno DS, Donner AL, Kopp SR, Yoest J, Mneimneh W, Margevicius S, Shanahan J, Fu P, Hsu ML, Afshin Dowlati A, Sadri N. Implementation of a precision medicine thoracic (PREDICT) service using reflex testing in a large academic-community practice network. Journal of Clinical Oncology 2022 40:16_suppl, 6572-6572.
https://ascopubs.org/doi/abs/10.1200/JCO.2022.40.16_suppl.6572

Sarcoma

von Mehren M, Litwin S, Ravi V, Shuetze S, Mowa S, Agulnik M, Kraft AS, Tetzlaff ED, Somaiah N. Multicenter Phase II Trial of Pazopanib (P) in Patients with Angiosarcoma (AS).  J Clin Onco 37, 2019 (suppl abstr 11039).
https://meetinglibrary.asco.org/record/174703/abstract